The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TTLC 2026 | Current PD-(L)1 and VEGF combinations and future bispecifics in NSCLC
Natalie Vokes, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the history and development of PD-(L)1 and VEGF combinations, as well as bispecifics, in the treatment of non-small cell lung cancer (NSCLC). Previous trials combining PD-1 inhibitors with VEGF inhibitors have shown mixed results, which often showed improvement in progression-free survival but not overall survival, and newer bispecifics may offer a more promising approach. This interview took place at International Association for the Study of Lung Cancer (IASLC) 2026 Targeted Therapies of Lung Cancer Meeting (TTLC) in Huntington Beach, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
